Director Leon Recanati Buys $400K Stake, Backs Incumbent Board in Proxy Fight
EVGN sits 84% above its 52-week low of $0.37 on elevated volume (4.0× avg).
Summary
Evogene director Leon Recanati purchased $400K of stock and pledged to vote for the incumbent board in the September 4 proxy fight against an activist group holding 17.4%.
Key Events · Ownership and Investor Activity · EVGN
-
Director Buys $400K Stake
Leon Recanati purchased 800,000 shares at $0.50 each, increasing his beneficial ownership to 894,836 shares (5.7% of outstanding).
-
Votes Pledged for Incumbent Board
Recanati will vote all his shares for the current board's nominees at the September 4, 2026 AGM, opposing the activist slate that holds 17.4%.
-
Proxy Battle Context
The activist group has been buying shares since July and now holds 17.41%, demanding board replacement. Recanati's purchase and voting commitment strengthens the incumbent position.
-
Financial Impact
The $400,000 purchase represents a significant personal investment relative to the company's ~$10M market cap, signaling strong insider conviction.
Analysis · EVGN · Industrial Applications And Services
In a high-stakes move ahead of the September 4 AGM, Director Leon Recanati has purchased 800,000 shares for ~$400,000 at $0.50 per share, lifting his stake to 5.7%. He is publicly committing to vote all his shares for the incumbent board, directly opposing the activist group that holds 17.4% and seeks to replace most directors. This real-money endorsement from an insider with a board seat materially shifts the voting dynamics in the proxy battle.
At the time of this filing, EVGN was trading at $0.68 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $10M. The 52-week trading range was $0.37 to $1.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.